Monte Rosa Therapeutics, Inc. - Common Stock

Share · US61225M1027 · GLUE (XNAS)

Overview

AI-Powered Analysis

Fundamental Analysis

Find out what the numbers really say — before the market does

Analyze now

News Sentiment

Are today's headlines a buy signal or a red flag?

Analyze now

Buy / Hold / Sell

Should you Buy, Hold, or Sell? Get the AI verdict now.

Analyze now

Risk Assessment

Uncover hidden risks before they hit your portfolio.

Analyze now

Fair Value

Is this stock cheap, fairly priced, or overvalued?

Analyze now

Latest AI Analyses of Monte Rosa Therapeutics, Inc. - Common Stock

Analyst Grade Summary

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

No Price

28.04.2026 20:00

Current Prices from Monte Rosa Therapeutics, Inc. - Common Stock

Exchange	Ticker	Currency	Last Trade	Price	Daily Change
NASDAQ	GLUE	USD	28.04.2026 20:00	19,01 USD	-0,28 USD -1,45 %
IEX	GLUE	USD	28.04.2026 19:59	19,02 USD	-0,27 USD -1,43 %

Share Float & Liquidity

Free Float 64,71 %

Shares Float 42,14 M

Shares Outstanding 65,12 M

Company Profile for Monte Rosa Therapeutics, Inc. - Common Stock Share

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.